The International Council for Harmonisation (ICH) provides harmonized guidelines that govern the quality, safety, and efficacy requirements for pharmaceutical products, including peptides. This guide covers the ICH guidelines most relevant to peptide drug development.
| Category | Organizations |
|---|
| Regulatory | FDA, EMA, PMDA, Health Canada, TGA, Swissmedic |
| Industry | PhRMA, EFPIA, JPMA |
| Observers | WHO, ISPE, DIA |
| Category | Series | Focus |
|---|
| Quality | Q | Pharmaceutical development, manufacturing |
| Safety | S | Non-clinical safety |
| Efficacy | E | Clinical evaluation |
| Multidisciplinary | M | Common technical document, medical terminology |
| Guideline | Title | Application to Peptides |
|---|
| Q1A(R2) | New Drug Substances and Products | Stability study design |
| Q1B | Photostability Testing | Light-sensitive peptide assessment |
| Q1C | Stability Testing for New Dosage Forms | If new formulation developed |
| Q1D | Bracketing and Matrixing Designs | Reduced stability study designs |
| Q1E | Evaluation of Stability Data | Statistical analysis of data |
| Q1F | Stability Data Packets (withdrawn) | Replaced by regional requirements |
| Study Condition | Temperature | Humidity | Duration | Testing Points |
|---|
| Long-term | 25°C ± 2°C | 60% ± 5% RH | 12–60 months | 0, 3, 6, 12, 18, 24, 36 mo |
| Accelerated | 40°C ± 2°C | 75% ± 5% RH | 6 months | 0, 3, 6 months |
| Intermediate | 30°C ± 2°C | 65% ± 5% RH | 12 months | 0, 6, 12 months |
| Degradation Pathway | Mechanism | Monitoring |
|---|
| Deamidation | Asn/Gln hydrolysis | RP-HPLC, MS |
| Oxidation | Met, Cys, Trp oxidation | RP-HPLC, MS |
| Aggregation | Physical association | SEC-HPLC, DLS |
| Hydrolysis | Peptide bond cleavage | RP-HPLC |
| Racemization | D/L isomerization | Chiral HPLC |
| Disulfide scrambling | S-S bond rearrangement | RP-HPLC (reduced/alkylated) |
| Depyration | Pyroglutamate formation | RP-HPLC, MS |
| Guideline | Title | Application |
|---|
| Q2(R1) | Validation of Analytical Procedures | Method validation parameters |
| Parameter | Definition | Acceptance Criterion |
|---|
| Specificity | Ability to measure analyte without interference | No interference from matrix |
| Linearity | Proportional relationship between response and concentration | r² > 0.999 |
| Accuracy | Closeness to true value | 98–102% recovery |
| Precision (Repeatability) | Agreement among results (same conditions) | RSD ≤1% |
| Precision (Intermediate) | Agreement among results (different conditions) | RSD ≤2% |
| Range | Interval of applicability | 80–120% of target |
| Quantitation Limit (LOQ) | Lowest quantifiable level | S/N ≥ 10 |
| Detection Limit (LOD) | Lowest detectable level | S/N ≥ 3 |
| Robustness | Ability to resist small variations | Demonstrated for critical parameters |
| Guideline | Title | Application to Peptides |
|---|
| Q3A(R2) | Impurities in New Drug Substances | Organic impurities in peptide API |
| Q3B(R2) | Impurities in New Drug Products | Degradation products in dosage form |
| Q3C(R8) | Residual Solvents | Solvent limits (DMF, NMP, TFA, ACN) |
| Q3D(R2) | Elemental Impurities | Metal catalysts, equipment-derived |
| Threshold | Calculation | Reporting |
|---|
| Reporting threshold | 0.05% (max daily dose ≤1 g) | Report all above |
| Identification threshold | 0.10% (max daily dose ≤1 g) | Identify and report |
| Qualification threshold | 0.15% (max daily dose ≤1 g) | Qualify with safety data |
| Solvent | Class | Limit (ppm) | Application in Peptides |
|---|
| DMF | 2 | 880 | SPPS solvent |
| NMP | 2 | 530 | SPPS solvent |
| TFA | 3 | 5,000 | Cleavage, HPLC |
| Acetonitrile | 2 | 410 | HPLC mobile phase |
| DCM | 2 | 600 | Extraction |
| HFIP | 2 | — | Dissolution |
| Ethanol | 3 | 5,000 | Purification |
| Isopropanol | 3 | 5,000 | Purification |
| Guideline | Title | Relevance to Peptides |
|---|
| Q5A | Viral Safety Evaluation | Relevant for larger peptides/proteins |
| Q5B | Analysis of Expression Construct | Recombinant peptide production |
| Q5C | Stability Testing | Applicable to peptide biologics |
| Q5D | Derivation and Characterization | Cell line characterization |
| Q5E | Comparability | Post-change comparability |
| Component | Application to Peptides |
|---|
| Test procedures | Analytical methods for release |
| Acceptance criteria | Purity, impurity limits |
| Justification | Scientific rationale for limits |
| Batch analysis | Historical data support |
| Test | Specification | Method |
|---|
| Identity | Matches reference | MS, AA analysis |
| Purity | ≥98.0% | RP-HPLC |
| Single specified impurity | ≤0.5% | RP-HPLC |
| Total impurities | ≤2.0% | RP-HPLC |
| Water | ≤2.0% | Karl Fischer |
| Residual solvents | Per Q3C | GC-HS |
| Counter ion | Within specification | IC |
| Endotoxin | ≤5 EU/mg | LAL/rFC |
| Particle size | Meets specification | Laser diffraction |
| Section | Application |
|---|
| Design and development | QbD approach to formulation |
| Drug product characterization | Critical quality attributes |
| Manufacturing process development | CPP identification |
| Control strategy | Design space establishment |
| Tool | Application |
|---|
| FMEA | Process risk assessment |
| HACCP | Contamination control |
| Risk ranking | Risk prioritization |
| Ishikawa | Root cause analysis |
| FTA | Failure mode investigation |
| Element | Description |
|---|
| Process performance monitoring | Ongoing process verification |
| Corrective action and preventive action | CAPA system |
| Change management | Change control system |
| Management review | Periodic quality review |
| Knowledge management | Lifecycle knowledge capture |
| Section | Application |
|---|
| General principles | API development |
| Concept of QbD | Design space for synthesis |
| Control strategy | CPP/CQA relationships |
| Changes to approved API | Post-approval changes |
| Element | Description |
|---|
| Established conditions | Regulatory commitments |
| Post-approval change management | PACMP |
| Product lifecycle management | Continuous improvement |
| Section | Application |
|---|
| General principles | Continuous vs batch |
| Control strategy | Real-time monitoring |
| Quality system requirements | PAT integration |
| Impurity Type | Source | Control |
|---|
| Truncated sequences | Incomplete coupling | HPLC purification |
| Deamidated variants | Asn/Gln degradation | Stability studies |
| Oxidized variants | Met/Cys oxidation | Inert atmosphere |
| D-amino acid isomers | Racemization | Chiral HPLC |
| Aggregates | Physical association | SEC-HPLC |
| Residual TFA | Cleavage/purification | Ion chromatography |
| Residual solvents | Synthesis/purification | GC-HS |
| Bacterial endotoxins | Environmental | LAL testing |
| Section | Contents |
|---|
| 2.3.S.1 | General information (name, structure) |
| 2.3.S.2 | Manufacture (process description, controls) |
| 2.3.S.3 | Characterization (structure, impurities) |
| 2.3.S.4 | Control of drug substance (specifications) |
| 2.3.S.5 | Reference standards |
| 2.3.S.6 | Container closure system |
| 2.3.S.7 | Stability |
- ICH Q7 is the primary GMP standard for peptide API manufacturing
- Q1A(R2) dictates stability study design with conditions specific to peptide degradation pathways
- Q2(R1) requires full method validation for all release and stability-indicating methods
- Q3A/B/C/D establish impurity thresholds and limits critical for peptide purity control
- Q6A defines specification requirements that must be justified with development data
- Q8-Q12 provide the framework for QbD, risk management, and lifecycle management
- Peptide-specific considerations include deamidation, oxidation, aggregation, and D-amino acid formation
- Regulatory submission requires comprehensive CMC documentation covering development through commercial manufacture
